EQS-Adhoc: Vitruvia Medical AG: Issue of 6.00% Convertibel Bond 2022-2025
- 87
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Financing
Convertible bond Vitruvia Medical AG ("Private Placement") 6.00% 2022-2025
By resolution of the Board of Directors, Vitruvia Medical AG has resolved to issue a convertible bond ("Private Placement") of CHF 2.2 million at an interest rate of 6.00% p.a. and a term of 3 years. The issue price is set at 100% and the conversion price is EUR 2.50 and is convertible into registered shares of Vitruvia Medical AG. The funds will be used to finance existing projects (LT technologies GmbH & Co. KG), acquisitions (rebuilding of the investment portfolio) and general corporate financing.
Anglikon, 26 November 2022 Vitruvia Medical Ltd. Board of directors
26-Nov-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Vitruvia Medical AG |
Kesselackerstr. 18 | |
5611 Anglikon | |
Switzerland | |
Phone: | +41 44 915 33 78 |
E-mail: | [email protected] |
Internet: | www.vitruvia-med.com |
ISIN: | CH0461931419 |
WKN: | A2PDWF |
Listed: | Regulated Unofficial Market in Munich |
EQS News ID: | 1498163 |
End of Announcement | EQS News Service |
|
1498163 26-Nov-2022 CET/CEST
EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.
- Life & Banc Split Corp. Completes Treasury Offering
- Samson Rock Capital LLP - Form 8.3 - Shanta Gold Ltd
- NT Solar Celebrates New Impact Investment Fund & Series of Successful Transactions
- Samson Rock Capital LLP - Form 8.3 - Network International Holdings Plc
- U.S. Gold Corp. Closes $4.9 Million Non-Brokered Registered Direct Offering
- JinkoSolar Files 2023 Annual Report on Form 20-F